Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer
- PMID: 27510421
- PMCID: PMC11107773
- DOI: 10.1007/s00018-016-2321-z
Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer
Abstract
TNF-related apoptosis-inducing ligand (TRAIL) is a prominent cytokine capable of inducing apoptosis. It can bind to five different cognate receptors, through which diverse intracellular pathways can be activated. TRAIL's ability to preferentially kill transformed cells makes it a promising potential weapon for targeted tumor therapy. However, recognition of several resistance mechanisms to TRAIL-induced apoptosis has indicated that a thorough understanding of the details of TRAIL biology is still essential before this weapon can be confidently unleashed. Critical to this aim is revealing the functions and regulation mechanisms of TRAIL's potent death receptor DR5. Although expression and signaling mechanisms of DR5 have been extensively studied, other aspects, such as its subcellular localization, non-signaling functions, and regulation of its membrane transport, have only recently attracted attention. Here, we discuss different aspects of TRAIL/DR5 biology, with a particular emphasis on the factors that seem to influence the cell surface expression pattern of DR5, along with factors that lead to its nuclear localization. Disturbance of this balance apparently affects the sensitivity of cancer cells to TRAIL-mediated apoptosis, thus constituting an eligible target for potential new therapeutic agents.
Keywords: DR4; DR5 internalization; DR5 nuclear localization; DR5 ubiquitination; HuR; Importin β1; TRAIL resistance; mRNA stabilization.
Conflict of interest statement
The authors declare no conflict of interests.
Figures


Similar articles
-
Importin β1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells.J Biol Chem. 2011 Dec 16;286(50):43383-93. doi: 10.1074/jbc.M111.309377. Epub 2011 Oct 21. J Biol Chem. 2011. PMID: 22020938 Free PMC article.
-
Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.Int J Oncol. 2018 Dec;53(6):2789-2799. doi: 10.3892/ijo.2018.4562. Epub 2018 Sep 14. Int J Oncol. 2018. PMID: 30221676
-
The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand.J Biol Chem. 2013 Oct 11;288(41):29923-33. doi: 10.1074/jbc.M113.483909. Epub 2013 Aug 28. J Biol Chem. 2013. PMID: 23986445 Free PMC article.
-
[Progress on targeting TRAIL's receptor as antitumor strategy].Yao Xue Xue Bao. 2009 Dec;44(12):1336-42. Yao Xue Xue Bao. 2009. PMID: 21351465 Review. Chinese.
-
Developing TRAIL/TRAIL death receptor-based cancer therapies.Cancer Metastasis Rev. 2018 Dec;37(4):733-748. doi: 10.1007/s10555-018-9728-y. Cancer Metastasis Rev. 2018. PMID: 29541897 Free PMC article. Review.
Cited by
-
sDR5-Fc inhibits macrophage M1 polarization by blocking the glycolysis.J Geriatr Cardiol. 2021 Apr 28;18(4):271-280. doi: 10.11909/j.issn.1671-5411.2021.04.003. J Geriatr Cardiol. 2021. PMID: 33995506 Free PMC article.
-
Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway.Cell Death Discov. 2019 Dec 10;5:153. doi: 10.1038/s41420-019-0228-9. eCollection 2019. Cell Death Discov. 2019. PMID: 31839995 Free PMC article.
-
Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma.bioRxiv [Preprint]. 2025 May 30:2025.05.29.621197. doi: 10.1101/2025.05.29.621197. bioRxiv. 2025. PMID: 40501957 Free PMC article. Preprint.
-
Transcriptomics Profiling Identifies Cisplatin-Inducible Death Receptor 5 Antisense Long Non-coding RNA as a Modulator of Proliferation and Metastasis in HeLa Cells.Front Cell Dev Biol. 2021 Aug 23;9:688855. doi: 10.3389/fcell.2021.688855. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34497804 Free PMC article.
-
Rolapitant treats lung cancer by targeting deubiquitinase OTUD3.Cell Commun Signal. 2024 Mar 27;22(1):195. doi: 10.1186/s12964-024-01519-8. Cell Commun Signal. 2024. PMID: 38539203 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous